KLISYRI

This brand name is authorized in United States. It is also authorized in Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Spain.

Active ingredients

The drug KLISYRI contains one active pharmaceutical ingredient (API):

1	Tirbanibulin UNII 4V9848RS5G - TIRBANIBULIN
	Tirbanibulin disrupts microtubules by direct binding to tubulin, which induces cell cycle arrest and apoptotic death of proliferating cells, and is associated with disruption of Src tyrosine kinase signalling.
	Read more about Tirbanibulin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KLISYRI Ointment	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D06BX03		D Dermatologicals → D06 Antibiotics and chemotherapeutics for dermatological use → D06B Chemotherapeutics for topical use → D06BX Other chemotherapeutics
Discover more medicines within D06BX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1858080
ES	Centro de información online de medicamentos de la AEMPS	1211558001
FR	Base de données publique des médicaments	62644226
IT	Agenzia del Farmaco	049607017
LT	Valstybinė vaistų kontrolės tarnyba	1092973
PL	Rejestru Produktów Leczniczych	100449820
US	FDA, National Drug Code	16110-391